HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Posther, K. E. Articles by Siegel, B. A. Search for Related Content PubMed PubMed Citation Articles by Posther, K. E. Articles by Siegel, B. A.

Yield of Brain ¹⁸F-FDG PET in Evaluating Patients with Potentially Operable Non–Small Cell Lung Cancer

¹ Department of Surgery, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina; ² Department of Biostatistics, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina; ³ Thoracic Oncology Program, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina; ⁴ Division of Cardiothoracic Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina; ⁵ Vanderbilt University Medical Center, Nashville, Tennessee; ⁶ Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁷ Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

Correspondence: For correspondence or reprints contact: Barry A. Siegel, MD, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Blvd., St. Louis, MO 63110. E-mail: siegelb{at}mir.wustl.edu

The American College of Surgeons Oncology Group recently completed a trial evaluating the role of PET with ¹⁸F-FDG in patients with documented or suspected non–small cell lung cancer. Subjects underwent standard imaging to exclude metastatic disease before PET. Here, we report the yield of brain PET in evaluating, for potential intracranial metastases, patients who have undergone previous brain CT or MRI with negative findings. Methods: A total of 287 evaluable patients who had been registered from 22 institutions underwent whole-body ¹⁸F-FDG PET, including dedicated PET of the brain, after routine staging procedures had found no suggestion of metastatic disease. Patients were followed postoperatively for disease-free and overall survival, with a minimum follow-up of 6 mo. Patients with specific brain abnormalities identified by PET were further examined, and the findings were evaluated along with the results of CT and MRI, clinical management, and follow-up. Results: In 4 patients, PET found focal ¹⁸F-FDG uptake in the brain suggestive of metastatic disease; however, metastatic disease was excluded clinically in all 4 by negative findings on further brain imaging. All 4 patients remained alive at follow-up (mean duration, 10.5 mo; range, 6–16 mo). Conclusion: In patients with suspected or proven non–small cell lung cancer considered resectable by standard imaging, including routine preoperative contrast-enhanced CT or MRI of the brain, PET of the brain provides no additional information regarding metastatic disease.

Related articles in JNM:

This Month in JNM

JNM 2006 47: 9a-10a. [Full Text]  

This article has been cited by other articles:

				Notice of Correction: Results of ACOSOG Z0050 trial: The utility of FDG-PET in staging potentially operable non-small cell lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 864 - 864. [Full Text] [PDF]